<p>Immunovant, Inc.（纳斯达克代码：IMVT - 获取免费报告）在周四的交易中股价下跌了 6.4%，原因是该公司公布的季度收益低于预期。股价最低曾跌至 33.25 美元，最后交易价为 33.2950 美元。在午盘交易中，约有 1,378,728 股被交易，较日均交易量 1,611,508 股下降了 14%。该股此前收盘价为 35.56 美元。</p>
<p>该公司报告本季度每股收益（EPS）为（0.73）美元，低于分析师一致预期的（0.60）美元，差距为（0.13）美元。去年同期，该公司每股收益为（0.64）美元。</p>
<h2>Immunovant 新闻摘要</h2>
<p>以下是本周影响 Immunovant 的主要新闻：</p>
<ul>
<li>积极情绪：Immunovant 发布了其难治性类风湿关节炎研究的第 16 周强劲结果，反应率被投资者视为具有临床意义，并支持该药物的潜力。文章标题</li>
<li>积极情绪：该公司表示其皮肤性狼疮概念验证试验已完全招募，成为另一个近期催化剂，预计在 2026 年下半年发布顶线数据。文章标题</li>
<li>积极情绪：Immunovant 还强调截至季度末的现金余额约为 9.02 亿美元，这将支持持续开发并帮助资助 IMVT-1402 在格雷夫斯病中的潜在商业推出。文章标题</li>
</ul>
<h2>分析师评级变动</h2>
<p>多家股票研究分析师最近对 IMVT 股票发布了报告。HC Wainwright 在周四的研究报告中将 Immunovant 的目标价从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。美国银行在周四的研究报告中将 Immunovant 的目标价从 32.00 美元上调至 43.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 2 月 9 日的报告中将 Immunovant 的目标价从 41.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 4 月 8 日的报告中重申了对 Immunovant 股票的 “卖出（d-）” 评级。最后，Sanford C. Bernstein 在 3 月 20 日的报告中开始覆盖 Immunovant，给予 “市场表现” 评级和 28.00 美元的目标价。目前，六位分析师对该股给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunovant 目前的共识评级为 “持有”，共识目标价为 34.44 美元。</p>
<p><strong>获取我们对 Immunovant 的最新分析</strong></p>
<h2>Immunovant 内部交易</h2>
<p>在相关消息中，首席财务官 Tiago Girao 于 4 月 23 日（星期四）出售了 25,760 股公司的股票，交易价格为每股 29.62 美元，总价值为 763,011.20 美元。交易后，首席财务官直接持有 247,596 股公司股票，价值约为 7,333,793.52 美元。这代表其持股比例下降了 9.42%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，首席运营官 Melanie Gloria 于 4 月 8 日（星期三）出售了 8,722 股公司的股票，交易价格为每股 24.83 美元，总价值为 216,567.26 美元。交易完成后，首席运营官持有 245,222 股公司股票，价值为 6,088,862.26 美元。这代表其持股比例下降了 3.43%。有关此次出售的更多细节可在官方 SEC 披露中找到。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。在过去的九十天里，内部人士共出售了 78,141 股公司股票，价值为 2,115,713 美元。目前，1.80% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>对该公司的对冲基金和其他机构投资者最近调整了持股。Granahan Investment Management LLC 在第三季度将其在 Immunovant 的持股比例提高了 24.9%。Granahan Investment Management LLC 目前持有 266,221 股公司股票，价值为 4,291,000 美元，此前在上个季度增持了 53,133 股。阿伯丁集团（Aberdeen Group plc）在第三季度将其在 Immunovant 的持股比例提高了 16.2%。阿伯丁集团目前持有 981,804 股公司股票，价值为 15,827,000 美元，此前在上个季度增持了 137,099 股。阿尔卑斯全球管理（Alpine Global Management LLC）在第三季度将其在 Immunovant 的持股比例提高了 4.9%。阿尔卑斯全球管理目前持有 2,754,731 股公司股票，价值为 44,406,000 美元，此前在上个季度增持了 128,039 股。Hennion &amp; Walsh 资产管理公司在第四季度收购了 Immunovant 的新股份，价值为 1,823,000 美元。最后，高 Vista 策略（HighVista Strategies LLC）在第三季度将其在 Immunovant 的持股比例提高了 38.5%。高 Vista 策略目前持有 253,127 股公司股票，价值为 4,080,000 美元，此前在上个季度增持了 70,319 股。目前，47.08% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Immunovant 价格表现</h2>
<p>该公司的市值为 68.4 亿美元，市盈率为-12.45，贝塔系数为 0.70。该公司的 50 日移动平均价格为 26.48 美元，200 日移动平均价格为 25.78 美元。</p>
<h2>Immunovant 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunovant Inc 是一家临床阶段的生物制药公司，专注于开发针对新生儿 Fc 受体（FcRn）的新型单克隆抗体疗法，以治疗严重的自身免疫疾病。通过抑制 FcRn，Immunovant 的方案旨在降低致病性免疫球蛋白 G（IgG）抗体的水平，这些抗体在重症肌无力和免疫性血小板减少症等疾病的病理中发挥着核心作用。</p>
<p>该公司的主要资产 efgartigimod 是一种工程化的 Fc 片段，能够选择性地结合 FcRn，加速循环 IgG 的降解。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票超过 Immunovant</li>
<li>2 只将 AI 恐惧转化为基本面收益的软件股票</li>
<li>代币接管：SEC 引发市场震荡</li>
<li>Target 展现出强劲，但分析师希望看到更多</li>
<li>NVIDIA 价格回调？别指望，业务正在加速</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Immunovant 吗？</h2>
<p>在考虑 Immunovant 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Immunovant 并不在名单上。</p>
<p>虽然 Immunovant 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMVT

<p>Immunovant 的股票（NASDAQ:IMVT）在报告季度收益不佳后下跌 6.4%，至 33.2950 美元，亏损每股 0.73 美元，低于预期 0.13 美元。尽管如此，该公司拥有 9.02 亿美元的强大现金余额，并且在临床试验中有积极进展。分析师的评级不一，其中六个 “买入” 和一个 “卖出” 评级。内部交易显示出为满足税务义务而进行的大量股票出售</p>

<p>Immunovant, Inc. (NASDAQ:IMVT - Get Free Report)'s stock price was down 6.4% during trading on Thursday after the company announced weaker than expected quarterly earnings. The stock traded as low as $33.25 and last traded at $33.2950. Approximately 1,378,728 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 1,611,508 shares. The stock had previously closed at $35.56.</p>
<div class="lb-trans"><p>Immunovant, Inc.（纳斯达克代码：IMVT - 获取免费报告）在周四的交易中股价下跌了 6.4%，原因是该公司公布的季度收益低于预期。股价最低曾跌至 33.25 美元，最后交易价为 33.2950 美元。在午盘交易中，约有 1,378,728 股被交易，较日均交易量 1,611,508 股下降了 14%。该股此前收盘价为 35.56 美元。</p>
</div><p>The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.13). During the same quarter last year, the firm posted ($0.64) earnings per share.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益（EPS）为（0.73）美元，低于分析师一致预期的（0.60）美元，差距为（0.13）美元。去年同期，该公司每股收益为（0.64）美元。</p>
</div><h2>Immunovant News Summary</h2>
<div class="lb-trans"><h2>Immunovant 新闻摘要</h2>
</div><p>Here are the key news stories impacting Immunovant this week:</p>
<div class="lb-trans"><p>以下是本周影响 Immunovant 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Immunovant released strong Week 16 results from its difficult-to-treat rheumatoid arthritis study, with response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title</li>
<li>Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled, creating another near-term catalyst with topline data expected in the second half of 2026. Article Title</li>
<li>Positive Sentiment: Immunovant also highlighted a cash balance of about $902 million at quarter-end, which should support ongoing development and help fund a potential commercial launch of IMVT-1402 in Graves’ disease. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Immunovant 发布了其难治性类风湿关节炎研究的第 16 周强劲结果，反应率被投资者视为具有临床意义，并支持该药物的潜力。文章标题</li>
<li>积极情绪：该公司表示其皮肤性狼疮概念验证试验已完全招募，成为另一个近期催化剂，预计在 2026 年下半年发布顶线数据。文章标题</li>
<li>积极情绪：Immunovant 还强调截至季度末的现金余额约为 9.02 亿美元，这将支持持续开发并帮助资助 IMVT-1402 在格雷夫斯病中的潜在商业推出。文章标题</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities research analysts have recently issued reports on IMVT shares. HC Wainwright upped their price target on Immunovant from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday. Bank of America upped their price target on Immunovant from $32.00 to $43.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday. Guggenheim upped their price objective on Immunovant from $41.00 to $44.00 and gave the company a &#34;buy&#34; rating in a report on Monday, February 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Immunovant in a report on Wednesday, April 8th. Finally, Sanford C. Bernstein began coverage on Immunovant in a report on Friday, March 20th. They issued a &#34;market perform&#34; rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Immunovant presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $34.44.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对 IMVT 股票发布了报告。HC Wainwright 在周四的研究报告中将 Immunovant 的目标价从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。美国银行在周四的研究报告中将 Immunovant 的目标价从 32.00 美元上调至 43.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 2 月 9 日的报告中将 Immunovant 的目标价从 41.00 美元上调至 44.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 4 月 8 日的报告中重申了对 Immunovant 股票的 “卖出（d-）” 评级。最后，Sanford C. Bernstein 在 3 月 20 日的报告中开始覆盖 Immunovant，给予 “市场表现” 评级和 28.00 美元的目标价。目前，六位分析师对该股给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunovant 目前的共识评级为 “持有”，共识目标价为 34.44 美元。</p>
</div><p><strong>Get Our Latest Analysis on Immunovant</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Immunovant 的最新分析</strong></p>
</div><h2>Insider Transactions at Immunovant</h2>
<div class="lb-trans"><h2>Immunovant 内部交易</h2>
</div><p>In related news, CFO Tiago Girao sold 25,760 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $29.62, for a total value of $763,011.20. Following the transaction, the chief financial officer directly owned 247,596 shares in the company, valued at approximately $7,333,793.52. This represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Melanie Gloria sold 8,722 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $24.83, for a total value of $216,567.26. Following the completion of the transaction, the chief operating officer owned 245,222 shares in the company, valued at $6,088,862.26. This represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 78,141 shares of company stock valued at $2,115,713 in the last ninety days. 1.80% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Tiago Girao 于 4 月 23 日（星期四）出售了 25,760 股公司的股票，交易价格为每股 29.62 美元，总价值为 763,011.20 美元。交易后，首席财务官直接持有 247,596 股公司股票，价值约为 7,333,793.52 美元。这代表其持股比例下降了 9.42%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。此外，首席运营官 Melanie Gloria 于 4 月 8 日（星期三）出售了 8,722 股公司的股票，交易价格为每股 24.83 美元，总价值为 216,567.26 美元。交易完成后，首席运营官持有 245,222 股公司股票，价值为 6,088,862.26 美元。这代表其持股比例下降了 3.43%。有关此次出售的更多细节可在官方 SEC 披露中找到。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。在过去的九十天里，内部人士共出售了 78,141 股公司股票，价值为 2,115,713 美元。目前，1.80% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. Granahan Investment Management LLC raised its stake in shares of Immunovant by 24.9% in the third quarter. Granahan Investment Management LLC now owns 266,221 shares of the company's stock valued at $4,291,000 after acquiring an additional 53,133 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Immunovant by 16.2% in the third quarter. Aberdeen Group plc now owns 981,804 shares of the company's stock valued at $15,827,000 after acquiring an additional 137,099 shares in the last quarter. Alpine Global Management LLC raised its stake in shares of Immunovant by 4.9% in the third quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company's stock valued at $44,406,000 after acquiring an additional 128,039 shares in the last quarter. Hennion &amp; Walsh Asset Management Inc. acquired a new stake in shares of Immunovant in the fourth quarter valued at $1,823,000. Finally, HighVista Strategies LLC raised its stake in shares of Immunovant by 38.5% in the third quarter. HighVista Strategies LLC now owns 253,127 shares of the company's stock valued at $4,080,000 after acquiring an additional 70,319 shares in the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对该公司的对冲基金和其他机构投资者最近调整了持股。Granahan Investment Management LLC 在第三季度将其在 Immunovant 的持股比例提高了 24.9%。Granahan Investment Management LLC 目前持有 266,221 股公司股票，价值为 4,291,000 美元，此前在上个季度增持了 53,133 股。阿伯丁集团（Aberdeen Group plc）在第三季度将其在 Immunovant 的持股比例提高了 16.2%。阿伯丁集团目前持有 981,804 股公司股票，价值为 15,827,000 美元，此前在上个季度增持了 137,099 股。阿尔卑斯全球管理（Alpine Global Management LLC）在第三季度将其在 Immunovant 的持股比例提高了 4.9%。阿尔卑斯全球管理目前持有 2,754,731 股公司股票，价值为 44,406,000 美元，此前在上个季度增持了 128,039 股。Hennion &amp; Walsh 资产管理公司在第四季度收购了 Immunovant 的新股份，价值为 1,823,000 美元。最后，高 Vista 策略（HighVista Strategies LLC）在第三季度将其在 Immunovant 的持股比例提高了 38.5%。高 Vista 策略目前持有 253,127 股公司股票，价值为 4,080,000 美元，此前在上个季度增持了 70,319 股。目前，47.08% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Immunovant Price Performance</h2>
<div class="lb-trans"><h2>Immunovant 价格表现</h2>
</div><p>The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of -12.45 and a beta of 0.70. The firm has a 50 day moving average price of $26.48 and a 200-day moving average price of $25.78.</p>
<div class="lb-trans"><p>该公司的市值为 68.4 亿美元，市盈率为-12.45，贝塔系数为 0.70。该公司的 50 日移动平均价格为 26.48 美元，200 日移动平均价格为 25.78 美元。</p>
</div><h2>Immunovant Company Profile</h2>
<div class="lb-trans"><h2>Immunovant 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.</p>
<div class="lb-trans"><p>Immunovant Inc 是一家临床阶段的生物制药公司，专注于开发针对新生儿 Fc 受体（FcRn）的新型单克隆抗体疗法，以治疗严重的自身免疫疾病。通过抑制 FcRn，Immunovant 的方案旨在降低致病性免疫球蛋白 G（IgG）抗体的水平，这些抗体在重症肌无力和免疫性血小板减少症等疾病的病理中发挥着核心作用。</p>
</div><p>The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.</p>
<div class="lb-trans"><p>该公司的主要资产 efgartigimod 是一种工程化的 Fc 片段，能够选择性地结合 FcRn，加速循环 IgG 的降解。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Immunovant</li>
<li>2 Software Stocks Turning AI Fears Into Fundamental Gains</li>
<li>The Token Takeover: SEC Triggers Market Quake</li>
<li>Target Shows Strengths, But Analysts Want to See More</li>
<li>NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Immunovant</li>
<li>2 只将 AI 恐惧转化为基本面收益的软件股票</li>
<li>代币接管：SEC 引发市场震荡</li>
<li>Target 展现出强劲，但分析师希望看到更多</li>
<li>NVIDIA 价格回调？别指望，业务正在加速</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunovant Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Immunovant 吗？</h2>
</div><p>Before you consider Immunovant, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Immunovant 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Immunovant 并不在名单上。</p>
</div><p>While Immunovant currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunovant 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunovant（纳斯达克股票代码：IMVT）因收益令人失望，股价下跌 6.4%